Gilead is aiming to supply enough of the drug by the end of the year to treat more than 2 million COVID-19 patients, and agreed to send nearly all of its remdesivir supply to the United States through September. Earlier this week, a bipartisan group of state attorneys general urged the U.S. government to allow other companies to make Gilead’s remdesivir, to increase its availability and lower the price of the antiviral drug. Gilead said its manufacturing network for the drug had grown to more than 40 companies in North America, Europe and Asia to add capacity.
from Yahoo Finance https://ift.tt/2XxUaur
Leave a Reply